Disclaimer: All information on this section is of a general nature.
Before making any investment decision, you should consult your adviser.

Investment Ideas - BARD1 Life Sciences (BD1) on track for 2019 commercialisation

Since listing on the ASX in June 2016, BD1 has set a strong foundation for commencing, in the December half of 2017, the key clinical validation studies on its lead product - the BARD1 Lung Cancer Test.
17/01/2017 12:19:27 PM

Back to top